J. David Joyner
Known title: EVP&President-PharmacyServicesCIK: 0001515598
Associated companies
Transaction History
| CVS | ▼ Sell | Tax Withholding | 8,029 | $582K | 4/1/2026 | View on chart |
| CVS | ▲ Buy | Grant | 86,326 | $6.2M | 3/31/2026 | View on chart |
| CVS | ▼ Sell | Tax Withholding | 1,944 | $155K | 2/28/2026 | View on chart |
| CVS | ▼ Sell | Tax Withholding | 1,847 | $126K | 4/1/2025 | View on chart |
| CVS | ▼ Sell | Tax Withholding | 1,944 | $128K | 2/28/2025 | View on chart |
| CVS | ▲ Buy | Grant | 28,280 | $0 | 4/1/2024 | View on chart |
| CVS | ▼ Sell | Tax Withholding | 1,970 | $148K | 2/28/2024 | View on chart |
| CVS | ▲ Buy | Grant | 23,940 | $2.0M | 2/28/2023 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
CVS Health News: Caremark Shift, Settlement Deadline, Defensive Status
CVS Caremark is changing how patients access health services, according to a recent report. The company also faces a settlement claim deadline a month away, with guidance on how to receive the funds. Analysts note that CVS is among a few defensive healthcare stocks being watched as rates remain high, and it has recently outperformed market returns.
CVS Health News: Caremark Shift, Settlement Deadline, Defensive Status. CVS Caremark is changing how patients access health services, according to a recent report. The company also faces a settlement claim deadline a month away, with guidance on how to receive the funds. Analysts note that CVS is among a few defensive healthcare stocks being watched as rates remain high, and it has recently outperformed market returns.